CTOs on the Move

Stallergenes Greer

www.stallergenesgreer.com

 
Stallergenes Greer is a global biopharmaceutical company specializing in the diagnosis and treatment of respiratory allergies through the development and commercialization of Allergy Immunotherapy products and services. Our purpose is to enable people with allergies to live normal lives. With more than 1,400 employees worldwide, a presence in 75 countries, and manufacturing facilities in both Europe and the United States, Stallergenes Greer plc is the parent company of GREER Laboratories, Inc. (whose registered office is in the U.S.) and Stallergenes S.A.S. (whose registered office is in France). With complementary strengths, joint heritage and reputations, Stallergenes Greer is driving a continuing ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion

Executives

Name Title Contact Details

Similar Companies

Cognition Pharmaceuticals

Cognition Pharmaceuticals is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aristos

Aristos is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

All-american Allergy Alternatives

All-american Allergy Alternatives is a Appleton, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Smile Workshop

Smile Workshop is dedicated in giving families the services they really care about from their dentist. Pediatrics and accepting Medicaid!

Ohr Pharmaceutical

Ohr Pharmaceutical, Inc. (OHRP) is an ophthalmology research and development company. The company`s lead product, Squalamine (OHR-102), is currently being studied as an eye drop formulation in several company sponsored and investigator sponsored Phase II clinical trials for various back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, diabetic macular edema, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery.